keyword
MENU ▼
Read by QxMD icon Read
search

Depression, mood disorder, bipolar

keyword
https://www.readbyqxmd.com/read/28929992/mood-disorders-and-circulating-levels-of-inflammatory-markers-in-a-longitudinal-population-based-study
#1
J Glaus, R von Känel, A M Lasserre, M-P F Strippoli, C L Vandeleur, E Castelao, M Gholam-Rezaee, C Marangoni, E-Y N Wagner, P Marques-Vidal, G Waeber, P Vollenweider, M Preisig, K R Merikangas
BACKGROUND: There has been increasing evidence that chronic low-grade inflammation is associated with mood disorders. However, the findings have been inconsistent because of heterogeneity across studies and methodological limitations. Our aim is to prospectively evaluate the bi-directional associations between inflammatory markers including interleukin (IL)-6, tumor necrosis factor (TNF)-α and high sensitivity C-reactive protein (hsCRP) with mood disorders. METHODS: The sample consisted of 3118 participants (53...
September 20, 2017: Psychological Medicine
https://www.readbyqxmd.com/read/28922738/mixed-symptoms-in-major-depressive-and-bipolar-disorders-a-systematic-review
#2
REVIEW
Gustavo H Vázquez, María Lolich, Casimiro Cabrera, Ruzica Jokic, Dusan Kolar, Leonardo Tondo, Ross J Baldessarini
BACKGROUND: The DSM-5 mixed features specifier for mood disorders encourages renewed interest in mixed states and led us to pool research findings regarding prevalence of mixed features in episodes of major depressive (MDD) and bipolar disorders (BD). METHODS: We systematically searched to July 2017 for reports on mixed symptoms in depressive episodes of MDD and in depression and mania or hypomania in types I and II BD. For primary mood-states and diagnostic groups we compared rates of the presence of mixed symptoms: as defined by DSM-5 (≥3 features opposite to the dominant mood-polarity but not overlapping those of the primary disorder) or as having any ≥3 features of opposite polarity...
September 8, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28922729/lithium-induced-oxidative-damage-and-inflammation-in-the-rat-s-heart-protective-effect-of-grape-seed-and-skin-extract
#3
Ali Mezni, Hanène Aoua, Olfa Khazri, Ferid Limam, Ezzeddine Aouani
Lithium (Li) is a relevant mood stabilizer metal for the treatment of bipolar disorder (BD), as it protects from both depression and mania and reduces the risk of suicide. However, Lihas some clinical concerns as a narrow therapeutic index requiring routine monitoring of the serum level. The present study was designed to analyze the cardio-toxic side effect of Li and the ability of grape seed and skin extract (GSSE) to protect the heart against such toxicity. After 30days of exposure to Li (0, 2, 5 and 100mg/kg bw) and prevention with GSSE (4000mg/kg bw), rats were killed by decapitation and their heart processed for Li-induced oxidative stress...
September 14, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28918761/quality-of-life-in-bipolar-disorder-towards-a-dynamic-understanding
#4
E Morton, G Murray, E E Michalak, R W Lam, S Beaulieu, V Sharma, P Cervantes, S V Parikh, L N Yatham
BACKGROUND: Although quality of life (QoL) is receiving increasing attention in bipolar disorder (BD) research and practice, little is known about its naturalistic trajectory. The dual aims of this study were to prospectively investigate: (a) the trajectory of QoL under guideline-driven treatment and (b) the dynamic relationship between mood symptoms and QoL. METHODS: In total, 362 patients with BD receiving guideline-driven treatment were prospectively followed at 3-month intervals for up to 5 years...
September 18, 2017: Psychological Medicine
https://www.readbyqxmd.com/read/28918419/-about-the-association-between-antipsychotic-medication-and-cardiovascular-morbidity-epidemiology-and-possible-background-mechanisms
#5
Gabor Gaszner, Gabor Barna, Peter Dome
The history of antipsychotics began with the discovery of chlorpromazine in the 1950s. Since then this group of medications has become one of the most important element of the armamentarium of psychopharmacology. While initially these pharmacons were used in the treatment of psychotic states (including psychotic mania) in the last approximately 10-15 years new indications - such as treatment of depressive, manic and mixed states and also mood-stabilization in bipolar disorder and also the treatment of major depressive disorder - for several second-generation antipsychotic (SGA) agents have been introduced...
June 2017: Neuropsychopharmacologia Hungarica
https://www.readbyqxmd.com/read/28914726/pro-inflammatory-cytokines-mood-and-sleep-in-interepisode-bipolar-disorder-and-insomnia-a-pilot-study-with-implications-for-psychosocial-interventions
#6
Michael R Dolsen, Adriane M Soehner, Allison G Harvey
OBJECTIVE: Pro-inflammatory cytokines are associated with bipolar disorder (BD), but less is known about how cytokines function during the interepisode period. This study examined cytokines, mood symptoms, and sleep in individuals with interepisode BD with complaints of insomnia. We also investigated the effects of a BD-specific modification of cognitive behavior therapy for insomnia (CBTI-BP) on cytokine levels. METHODS: The 22 adults with interepisode BD Type I and insomnia were drawn from a subset of an NIMH-funded study...
September 13, 2017: Psychosomatic Medicine
https://www.readbyqxmd.com/read/28912037/the-role-of-mental-imagery-in-mood-amplification-an-investigation-across-subclinical-features-of-bipolar-disorders
#7
Caitlin O'Donnell, Martina Di Simplicio, Randi Brown, Emily A Holmes, Stephanie Burnett Heyes
Vivid emotional mental imagery has been identified across a range of mental disorders. In bipolar spectrum disorders - psychopathologies characterized by mood swings that alternate between depression and mania, and include irritability and mixed affect states - mental imagery has been proposed to drive instability in both 'positive' and 'negative' mood. That is, mental imagery can act as an "emotional amplifier". The current experimental study tested this hypothesis and investigated imagery characteristics associated with mood amplification using a spectrum approach to psychopathology...
August 18, 2017: Cortex; a Journal Devoted to the Study of the Nervous System and Behavior
https://www.readbyqxmd.com/read/28902525/lurasidone-efficacy-and-safety-in-the-treatment-of-psychotic-and-mood-disorders
#8
Maurizio Pompili, Claudio Verzura, Giada Trovini, Andrea Buscajoni, Giulia Falcone, Stefano Naim, Adele Nardella, Serena Sorice, Ross J Baldessarini, Paolo Girardi
Lurasidone ([3aR,4S,7R,7aS]-2-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1yl-methyl] cyclohexylmethyl]-hexahydro-4,7-methano-2H-isoindole-1,3-dione hydrochloride; Latuda® [LRSD]) is a novel benzisothiazole, second-generation antipsychotic drug developed by Dainippon Sumitomo Pharma Corporation in Japan. Similar to other atypical antipsychotics it has a distinctive pharmacodynamic profile, Areas covered: This review updates reported research findings on the efficacy, safety and tolerability of LRSD for treatment of psychotic and major affective disorders, with meta-analyses...
September 13, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28892068/dysregulation-of-objectively-assessed-24-hour-motor-activity-patterns-as-a-potential-marker-for-bipolar-i-disorder-results-of-a-community-based-family-study
#9
H Shou, L Cui, I Hickie, D Lameira, F Lamers, J Zhang, C Crainiceanu, V Zipunnikov, K R Merikangas
There has been a growing number of studies that have employed actigraphy to investigate differences in motor activity in mood disorders. In general, these studies have shown that people with bipolar disorders (BPDs) tend to exhibit greater variability and less daytime motor activity than controls. The goal of this study was to examine whether patterns of motor activity differ in euthymic individuals across the full range of mood disorder subtypes (Bipolar I (BPI), Bipolar II (BPII) and major depression (MDD)) compared with unaffected controls in a community-based family study of mood spectrum disorders...
August 22, 2017: Translational Psychiatry
https://www.readbyqxmd.com/read/28889048/mania-triggered-by-sleep-loss-and-risk-of-postpartum-psychosis-in-women-with-bipolar-disorder
#10
Katie J S Lewis, Arianna Di Florio, Liz Forty, Katherine Gordon-Smith, Amy Perry, Nick Craddock, Lisa Jones, Ian Jones
BACKGROUND: Women with bipolar disorder are at high risk of affective psychoses following childbirth (i.e. "postpartum psychosis", PP) and there is a need to identify which factors underlie this increased risk. Vulnerability to mood dysregulation following sleep loss may influence risk of PP, as childbirth is typified by sleep disruption. We investigated whether a history of mood episodes triggered by sleep loss was associated with PP in women with bipolar disorder (BD). METHODS: Participants were 870 parous women with BD recruited to the Bipolar Disorder Research Network...
August 18, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28888714/the-diagnosis-and-management-of-bipolar-i-and-ii-disorders-clinical-practice-update
#11
REVIEW
William V Bobo
Bipolar disorders, including bipolar I disorder (BP-I) and bipolar II disorder (BP-II), are common, potentially disabling, and, in some cases, life-threatening conditions. Bipolar disorders are characterized by alternating episodes of mania or hypomania and depression, or mixtures of manic and depressive features. Bipolar disorders present many diagnostic and therapeutic challenges for busy clinicians. Adequate management of bipolar disorders requires pharmacotherapy and psychosocial interventions targeted to the specific phases of illness...
September 6, 2017: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/28882405/efficacy-of-quetiapine-xr-vs-placebo-as-concomitant-treatment-to-mood-stabilizers-in-the-control-of-subthreshold-symptoms-of-bipolar-disorder-results-from-a-pilot-randomized-controlled-trial
#12
Marina Garriga, Eva Solé, Ana González-Pinto, Gabriel Selva-Vera, Belén Arranz, Benedikt L Amann, Jerónimo Saiz-Ruiz, Josefina Pérez-Blanco, Eduard Vieta
Patients with bipolar disorder (BD) do not always achieve full remission between episodes. Subthreshold symptoms (depressive, manic or mixed) represent a major cause of relapse and disability in these patients. Immediate release (IR) and extended release (XR) formulations of quetiapine are both indicated for short and long-term treatment of BD. The aim of this study was to evaluate the efficacy of quetiapine XR vs placebo in subthreshold symptomatology when added to previous mood stabilizer treatment. A pilot phase IIIB, multicentre, prospective, placebo controlled, randomized, double blinded study of 12 weeks follow-up was performed (NCT01197846)...
September 4, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28881294/sleep-disturbance-may-impact-treatment-outcome-in-bipolar-disorder-a-preliminary-investigation-in-the-context-of-a-large-comparative-effectiveness-trial
#13
Louisa G Sylvia, Weilynn C Chang, Masoud Kamali, Mauricio Tohen, Gustavo Kinrys, Thilo Deckersbach, Joseph R Calabrese, Michael E Thase, Noreen Reilly-Harrington, William V Bobo, James H Kocsis, Melvin G McInnis, Charles L Bowden, Terence A Ketter, Edward S Friedman, Richard C Shelton, Susan L McElroy, Keming Gao, Dustin J Rabideau, Andrew A Nierenberg
BACKGROUND: Bipolar patients experience sleep disturbances during and between mood episodes. Yet the impact of sleep on treatment with different medications has not been fully explored. The purpose of this paper is to explore the potential impact of poor sleep at baseline on outcomes in a randomized effectiveness trial of quetiapine and lithium. METHODS: The Bipolar CHOICE study was a 6-month, parallel group, multisite randomized controlled trial. Participants with bipolar disorder (N = 482; 59% female and age 18-70 years) received quetiapine or lithium...
August 19, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28867303/treatment-with-a-glp-1r-agonist-over-four-weeks-promotes-weight-loss-moderated-changes-in-frontal-striatal-brain-structures-in-individuals-with-mood-disorders
#14
Rodrigo B Mansur, Andre Zugman, Juhie Ahmed, Danielle S Cha, Mehala Subramaniapillai, Yena Lee, Julie Lovshin, Jung G Lee, Jae-Hon Lee, Vladislav Drobinin, Jason Newport, Elisa Brietzke, Eva Z Reininghaus, Kang Sim, Maj Vinberg, Natalie Rasgon, Tomas Hajek, Roger S McIntyre
Cognitive deficits are a core feature across psychiatric disorders. Emerging evidence indicates that metabolic pathways are highly relevant for the substrates and phenomenology of the cognitive domain. Herein, we aimed to determine the effects of liraglutide, a GLP-1R agonist, on brain structural/volumetric parameters in adults with a mood disorder. This is the secondary analysis of a 4-week, pilot, proof-of-concept, open-label study. Participants (N=19) exhibiting impairments in executive function with either major depressive disorder (MDD) or bipolar disorder (BD) were recruited...
August 31, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28867283/kynurenic-acid-is-reduced-in-females-and-oral-contraceptive-users-implications-for-depression
#15
Timothy B Meier, Wayne C Drevets, T Kent Teague, Brent E Wurfel, Sven C Mueller, Jerzy Bodurka, Robert Dantzer, Jonathan Savitz
The incidence of depression is approximately 2-fold greater in women than men but the biological mechanisms underlying this phenomenon remain unclear. One potential mechanism that has been understudied is immune function, which is modulated by sex hormones and differs considerably between males and females. The immune-regulating kynurenine pathway previously has been implicated in the pathogenesis of mood disorders. In particular, a decreased ratio of neuroprotective (kynurenic acid; KynA) to neurotoxic (3-hydroxykynurenine; 3HK and quinolinic acid; QA) kynurenine pathway metabolites has been reported in several mood disorder subtypes...
September 1, 2017: Brain, Behavior, and Immunity
https://www.readbyqxmd.com/read/28866718/hypersomnia-and-cognitive-impairment-in-a-patient-with-bipolar-disorder-a-case-report
#16
Katarzyna Szaulińska, Anna Antosik-Wójcińska, Ewa Paszkowska, Łukasz Święcicki, Marek Jarema, Adam Wichniak
OBJECTIVES: Obstructive sleep apnea (OSA) is a common clinical problem that can have serious health consequences and complicate the course of mental disorders. It is estimated that the prevalence of sleep apnea in patients with bipolar disorder can be 21-47.5%. Some symptoms of OSA are the same as the symptoms of depression: daytime drowsiness, cognitive dysfunction, decreased drive, apathy, depressed mood, anhedonia. METHODS: We present a case of a patient whose depressive symptoms persisted despite repeated changes of pharmacological treatment and were exacerbated by severe sleep disorder...
June 18, 2017: Psychiatria Polska
https://www.readbyqxmd.com/read/28865715/plasma-oxytocin-levels-in-major-depressive-and-bipolar-ii-disorders
#17
Yueh-Ju Lien, Hui Hua Chang, Hsin-Chun Tsai, Yen Kuang Yang, Ru-Band Lu, Po See Chen
Oxytocin may play a role in mood regulation. Research has shown the plasma oxytocin level of patients with bipolar I disorder (BD I) during a manic episode was significantly higher than that of BD I patients of other statuses, and also that of healthy subjects. However, whether or not a difference in the level of oxytocin exists between patients with major depressive disorder (MDD) and those with BD II is unclear. This study aimed to investigate the plasma oxytocin levels in MDD and BD II patients in a depressive episode...
August 30, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28863299/sensory-profiles-as-potential-mediators-of-the-association-between-hypomania-and-hopelessness-in-488-major-affective-outpatients
#18
Batya Engel-Yeger, Xenia Gonda, Giovanna Canepa, Maurizio Pompili, Zoltan Rihmer, Mario Amore, Gianluca Serafini
INTRODUCTION: Extreme sensory processing patterns may contribute to the pathophysiology of major affective disorders. We aimed to examine whether significant correlations exist between sensory profiles, hypomania, self-reported depression, and hopelessness and whether sensory profiles may be potential mediators of the association between hypomania and depression/hopelessness. METHODS: The sample consisted of 488 euthymic affective disorder patients of which 283 diagnosed with unipolar and 162 with bipolar disorder with an age ranging from 18 to 65 years (mean = 47...
August 18, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28862044/acute-lamotrigine-overdose-a-systematic-review-of-published-adult-and-pediatric-cases
#19
Bader Alyahya, Marjorie Friesen, Bénédicte Nauche, Martin Laliberté
CONTEXT: Lamotrigine is a broad-spectrum anticonvulsant commonly used to treat seizure and bipolar mood disorders. Evidence from case series and retrospective studies indicate that lamotrigine overdose is usually benign. However, there are reported cases of cardiac arrest and mortality following lamotrigine overdose. We undertook a systematic review of the literature on lamotrigine overdoses to better understand the clinical severity, the relevance of serum concentrations, and therapeutic interventions for overdose...
September 1, 2017: Clinical Toxicology
https://www.readbyqxmd.com/read/28860774/bipolar-ii-disorder-as-the-initial-presentation-of-cadasil-an-underdiagnosed-manifestation
#20
Jianjun Wang, Jinfang Li, Fanxin Kong, Hanqing Lv, Zhouke Guo
Mood disturbances have been documented in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). The highly varied morbidity indicates that the affective symptoms in CADASIL have not been cataloged systematically, leading to ineffective treatment, affecting the patients' quality of life, and possibly resulting in suicide. We present a case of CADASIL with bipolar II disorder as the first manifestation. A middle-aged female reported recurrent depressive episodes and appeared treatment resistant to adequate dosages and durations of antidepressants...
2017: Neuropsychiatric Disease and Treatment
keyword
keyword
57037
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"